Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06979336 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
A Phase 2 study of Ulcerative Colitis, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
- 20
- Study locations
NCT06979336 is a Phase 2 study of Ulcerative Colitis that is actively recruiting participants, run by Genentech. The registered enrollment target is 224 participants, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT06979336, a Phase 2 study of Ulcerative Colitis, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.
Conditions Studied
Interventions
- DRUG RO7837195
- DRUG RO7837195 Matched Placebo
Study Locations (20)
Other
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University - Hangzhou
- PreventaMed, s.r.o. - Olomouc
- Nemocnice Slany - Slaný
California
- Gastro Care Institute - Lancaster
- Medical Associates Research Group, Inc. - San Diego
Lombardy
- Fondazione Poliambulanza Istituto Ospedaliero - Brescia
- ASST Rhodense, Rho Memorial Hospital - Rho
Colorado
- Peak Gastroenterology Associates - Colorado Springs
Florida
- Clinical Research of Osceola, LLC - Kissimmee
New York
- Intercity Gastroenterology - Fresh Meadows
North Carolina
- Monroe Biomedical Research - Monroe
Paraná
- Centro Digestivo de Curitiba - Curitiba
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2028-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06979336
The ClinicalTrials.gov registry entry for NCT06979336 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (89% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which RO7837195 is the first listed.
NCT06979336 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, California, Lombardy.
Frequently Asked Questions
What is clinical trial NCT06979336 about?
NCT06979336 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)". The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.
What is the current status of trial NCT06979336?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2025-09-29. Estimated completion is 2028-10-31.
What conditions does trial NCT06979336 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT06979336?
The interventions under investigation include: RO7837195 (DRUG), RO7837195 Matched Placebo (DRUG).
Who is sponsoring clinical trial NCT06979336?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06979336 being conducted?
This trial has 20 study locations across California, Colorado, Florida, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.